Trial Profile
Phase II Exploratory Study Of AG-858 Plus Gleevec In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2016
Price :
$35
*
At a glance
- Drugs AG 858 (Primary) ; Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Nov 2006 Status change
- 05 Sep 2005 New trial record.